IBIS II: A randomised phase III trial of anastrozole for breast cancer prevention in postmenopausal women at high risk.

IBIS II：一项阿那曲唑用于预防高危绝经后女性乳腺癌的随机 III 期试验。

• 批准号: nhmrc : 569213
• 负责人: Prof Alan Coates
• 金额: $ 115.53万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ibis-ii-randomised-high-risk/101305
• 关键词: IBIS; II; randomised; phase; III

The IBIS II trial builds on the successful IBIS 1 breast cancer (BC) prevention trial in determining whether a chemopreventive strategy towards BC is beneficial. Women who are postmenopausal with an increased risk of BC are randomised to receive either anastrozole (an aromatase inhibitor) or placebo as a daily tablet. Neither the woman nor her clinician know which treatment has been allocated (double blind study). IBIS 2 has the potential to benefit many higher risk women worldwide.

IBIS II试验建立在成功的IBIS 1乳腺癌（BC）预防试验的基础上，以确定对BC的化学预防策略是否有益。绝经后BC风险增加的妇女随机接受阿那曲唑（一种芳香酶抑制剂）或安慰剂每日片剂。女性和她的临床医生都不知道分配了哪种治疗（双盲研究）。IBIS 2有可能使全球许多高风险妇女受益。